Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Gilead (GILD) Plans European Regulatory Application in Early 2017 for Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients

Source Link:: http://www.gilead.com/news/press-releases/2016/10/gilead-announces-svr12-rates-from-four-phase-3-studies-of-a-oncedaily-fixeddose-combination-of-sofosbuvir-velpatasvir-and-voxilaprevir-in-treatmentna%C3%AFve-and-treatmentexperienced-genotype-16-chronic-hcvinfected-patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

GILD

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Management Comment “Based on these Phase 3 results, we plan to submit regulatory applications for SOF/VEL/VOX for the treatment of chronic HCV in the United States in the fourth quarter of 2016 and shortly thereafter in Europe.”

Norbert Bischofberger, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer at Gilead

http://www.gilead.co...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jan 20, 2017

Occurred Source:

http://www.gilead.com/news/press-releases/2017/1/european-medicines-agency-validates-gileads-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-sofosbuvirvelpatasvirvoxilaprevir-sofvelvox

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords European Medicines Agency, Sofosbuvir, Velpatasvir, Voxilaprevir, Treatment-experienced, Genotype 1-6, Chronic Hcv